Abstract
Background: In the Reduction of Endpoints in NIDDM (noninsulin–dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan study (RENAAL study), Losartan reduced the risk of the doubling of serum creatinine concentration by 25% and of end stage renal disease (ESRD) by 28%. Methods: 40 albino rats were enrolled in this study, and they were divided into four main groups, each group 10 rats. Where, group I, serves as a control, and group II was treated with Gentamicin 80mg/kg. The group III was treated with Losartan. While, group IV was treated with Losartan and Gentamicin. Results: Showed that Losartan has statistically significant nephro-protective effects. Their nephroprotective effects were assessed by:-1- histopathological studies. 2- Measuring serum levels of BUN, and, creatinnine. Conclusion: Losartan has renal-protective effects.
Highlights
Losartan 50 mg resulted in significant reductions of systolic and diastolic blood pressure at 24 hours after dosing
In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study (RENAAL study), Losartan reduced the risk of the doubling of serum creatinine concentration by 25% and of end stage renal disease (ESRD) by 28% [2]
This level showed no significant change compared to control group (28.2±1.5mg/dl), This study found that gentamicin and Losartan treated group, thier mean serum urea levels was 60.4±1.2 mg/dl
Summary
Losartan 50 mg resulted in significant reductions of systolic and diastolic blood pressure at 24 hours after dosing. In patients with type 2 diabetes mellitus, Angiotensin II receptor blockers (ARBs) are especially effective for decreasing nephropathy progression rate, independent of their blood pressure–lowering effect. In the Reduction of Endpoints in NIDDM (noninsulin–dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan study (RENAAL study), Losartan reduced the risk of the doubling of serum creatinine concentration by 25% and of end stage renal disease (ESRD) by 28%. Results: Showed that Losartan has statistically significant nephro-protective effects. Their nephroprotective effects were assessed by:-1- histopathological studies.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
